DNA Script company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

dnascript.com

Total Raised

$335.04M

Investors Count

29

Deal Terms

1

DNA Script Funding, DNA Script Valuation & DNA Script Revenue

10 Fundings

DNA Script's latest funding round was a Series C - II for $35M on January 4, 2022.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/4/2022

Series C - II

$35M

0

FY undefined

6

11/9/2021

Grant - V

$2.2M

0

FY undefined

6

10/26/2021

Series C

$165M

0

FY undefined

17

4/27/2021

Grant - IV

0

FY undefined

10

7/29/2020

Series B - II

$99M

0

FY undefined

10

DNA Script Deal Terms

1 Deal Term

DNA Script's deal structure is available for 1 funding round, including their Series A from September 12, 2017.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

DNA Script Investors

29 Investors

DNA Script has 29 investors. Irving Investors invested in DNA Script's Series C - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/4/2022

1/4/2022

1
Series C - II

Private Equity

Colorado

1/4/2022

1/4/2022

1
Series C - II

Asset/Investment Management

United Kingdom

1/4/2022

1/4/2022

1
Series C - II

Corporation

China

00/00/0000

00/00/0000

HealthCor Management

Subscribe to see more

Private Equity

New York

00/00/0000

00/00/0000

eureKARE

Subscribe to see more

Corporation

Luxembourg

First funding

1/4/2022

1/4/2022

1/4/2022

00/00/0000

00/00/0000

Last Funding

1/4/2022

1/4/2022

1/4/2022

00/00/0000

00/00/0000

Investor

HealthCor Management

eureKARE

Rounds

1
Series C - II
1
Series C - II
1
Series C - II

Subscribe to see more

Subscribe to see more

Board Seats

Type

Private Equity

Asset/Investment Management

Corporation

Private Equity

Corporation

Location

Colorado

United Kingdom

China

New York

Luxembourg

You May Also Like

Kilobaser Logo
Kilobaser

KioBaser is building what it dubs "Nespresso machine of DNA synthesis". The machine creates DNA primers, a short single strand of RNA or DNA (generally about 18-22 bases) that serves as a starting point for DNA synthesis.

Evonetix Logo
Evonetix

Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with application across industries including healthcare, pharma, biotech, food and agriculture and data storage.

Molecular Assemblies Logo
Molecular Assemblies

Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing) and advanced agricultural and industrial products, through gene development and DNA-based data storage.

H
Helixworks Technologies

Helixworks Technologies is a biotechnology company specializing in DNA synthesis.

I
Iridia

Iridia is developing a DNA-based data storage solution. By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridia is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density.

S
Synthomics

Developer of instrumentation for gene synthesis analysis. The company develops a DNA and RNA synthesizer for molecular biology research purposes. The platform aims to deliver less expensive, higher quality, reduced turn-around-time oligonucleotide synthesis solutions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.